[The clinical significance of determining the HLA-DR4 antigen in patients with breast cancer].
A study of HLA phenotype in 151 cases of breast cancer showed an increased occurrence of DR4 antigen (46.8%) as compared to general population (16.3%). Some clinical parameters of DR4-positive and DR4-negative patients were compared. Estradiol receptor-negative tumor was observed in 40% of DR4-positive patients and only in 18.5% of estradiol receptor-negative ones. DR4 positivity was associated with poorer prognosis.